Zacks Rating on Quest Diagnostics Incorporated (DGX)

Quest Diagnostics Incorporated (DGX) : 14 analysts are covering Quest Diagnostics Incorporated (DGX) and their average rating on the stock is 3.02, which is read as a Hold. 1 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. 1 more analyst has given the stock a Sell recommendation. A total of 11 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Quest Diagnostics Incorporated (DGX) has been rated by 10 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $90 and the lowest price target forecast is $70. The average forecast of all the analysts is $79.9 and the expected standard deviation is $6.42.


Quest Diagnostics Inc. has dropped 0.9% in the last five trading days, however, the shares have posted positive gains of 0.04% in the last 4 weeks. Quest Diagnostics Inc. is up 9.38% in the last 3-month period. Year-to-Date the stock performance stands at 20.67%. Quest Diagnostics Incorporated (NYSE:DGX): On Tuesdays trading session , Opening price of the stock was $85.3 with an intraday high of $85.45. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $84.38. However, the stock managed to close at $84.48, a loss of 0.73% for the day. On the previous day, the stock had closed at $85.1. The total traded volume of the day was 1,363,606 shares.

Quest Diagnostics Incorporated is a provider of diagnostic testing information services. The Company consists of two businesses: Diagnostic Information Services and Diagnostic Solutions. Diagnostic Information Services business, consists of two parts, develops and delivers diagnostic testing, information and services to patients, physicians, health plans, hospitals, accountable care organizations (ACOs), integrated delivery networks (IDNs), other commercial laboratories, patients and other customers. Diagnostics Information Services business also provides diagnostic information services, which includes providing clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services and drugs-of-abuse testing. Diagnostic Solutions includes the Companys other businesses, including central laboratory testing for pharmaceutical and medical device clinical trials, risk assessment services, diagnostic products and healthcare information technology.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.